Printed from https://ideas.repec.org/s/spr/pharmo3.html
Content
March 2020, Volume 4, Issue 1
- 191-201 Symptoms and Dietary Impact in Hypertriglyceridemia-Associated Pancreatitis: Development and Content Validity of Two New Measures
by Claire Burbridge & Jason A. Randall & Robert J. Sanchez & Hayes Dansky & Tara Symonds & Cynthia J. Girman & Joshua A. Strayer & Karen L. Selk & David C. Whitcomb & Erin E. Kershaw
December 2019, Volume 3, Issue 4
- 433-435 Check Your Checklist: The Danger of Over- and Underestimating the Quality of Economic Evaluations
by Geert W. J. Frederix - 437-451 A Comparison of Pharmaceutical Budget Impact Analysis (BIA) Recommendations Amongst the Canadian Patented Medicine Prices Review Board (PMPRB), Public and Private Payers
by Naghmeh Foroutan & Jean-Eric Tarride & Feng Xie & Fergal Mills & Mitchell Levine - 453-461 Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Nigel Fleeman & James Mahon & Sarah Nevitt & Rui Duarte & Angela Boland & Eleanor Kotas & Yenal Dundar & Joanne McEntee & Sajjad Ahmad - 463-478 Economic Burden and Health-Related Quality of Life Associated with Current Treatments for Anaemia in Patients with CKD not on Dialysis: A Systematic Review
by Pablo E. Pergola & Roberto Pecoits-Filho & Wolfgang C. Winkelmayer & Bruce Spinowitz & Samuel Rochette & Philippe Thompson-Leduc & Patrick Lefebvre & Gigi Shafai & Ana Bozas & Myrlene Sanon & Holly B. Krasa - 479-493 A Systematic Review of the Health Economics of Pompe Disease
by Benedikt Schoser & Andreas Hahn & Emma James & Digant Gupta & Matthew Gitlin & Suyash Prasad - 495-504 Person-Centred Care in Patients with Acute Coronary Syndrome: Cost-Effectiveness Analysis Alongside a Randomised Controlled Trial
by Laura Pirhonen & Kristian Bolin & Elisabeth Hansson Olofsson & Andreas Fors & Inger Ekman & Karl Swedberg & Hanna Gyllensten - 505-515 Cost-Effectiveness Analysis of Lopinavir/Ritonavir Monotherapy Versus Standard Combination Antiretroviral Therapy in HIV-1 Infected Patients with Viral Suppression in France (ANRS 140 DREAM)
by Osvaldo Ulises Garay & Marie Libérée Nishimwe & Marwân-al-Qays Bousmah & Asmaa Janah & Pierre-Marie Girard & Geneviève Chêne & Laetitia Moinot & Luis Sagaon-Teyssier & Jean-Luc Meynard & Bruno Spire & Sylvie Boyer - 517-526 National Health Insurance Databases in Indonesia, Vietnam and the Philippines
by Junice Yi Siu Ng & Royasia Viki Ramadani & Donni Hendrawan & Duong Tuan Duc & Pham Huy Tuan Kiet - 527-535 Use of Initial Noninvasive Cardiac Testing and Association with Downstream Healthcare Resource: A Retrospective Review of Resources Used Across a 12-Month Window for Probable Type I Myocardial Infarction Patients
by Dana Villines & Wm. Thomas Summerfelt & James R. Spalding & Therese M. Kitt & Rita M. Kristy & Christy R. Houle - 537-550 Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
by Pierre Johansen & Jonas Håkan-Bloch & Aiden R. Liu & Peter G. Bech & Sofie Persson & Lawrence A. Leiter - 551-558 Using Time Trade-Off Methods to Elicit Short-Term Utilities Associated with Treatments for Bulbar Urethral Stricture
by Jing Shen & Matthew Breckons & Luke Vale & Robert Pickard - 559-570 Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK
by Claire Telford & Evelina Bertranou & Samuel Large & Hilary Phelps & Mattias Ekman & Christopher Livings - 571-581 Using a Discrete-Choice Experiment to Estimate the Preferences of Clinical Practitioners for a Novel Non-invasive Device for Diagnosis of Peripheral Arterial Disease in Primary Care
by Yemi Oluboyede & Laura Ternent & Luke Vale & John Allen - 583-589 Analysis of Health Technology Assessments of Orphan Drugs in Ireland from 2012 to 2017
by Cara Usher & Laura McCullagh & Lesley Tilson & Michael Barry - 591-597 The Costs of Industry-Sponsored Medical Device Clinical Trials in Alberta
by Ilke Akpinar & Arto Ohinmaa & Lars Thording & Dat T. Tran & Richard N. Fedorak & Lawrence Richer & Philip Jacobs - 599-618 Long-Term Inpatient Hospital Utilisation and Costs (2007–2008 to 2015–2016) for Publicly Waitlisted Bariatric Surgery Patients in an Australian Public Hospital System Based on Australia’s Activity-Based Funding Model
by Julie A. Campbell & Martin Hensher & Daniel Davies & Matthew Green & Barry Hagan & Ian Jordan & Alison Venn & Alexandr Kuzminov & Amanda Neil & Stephen Wilkinson & Andrew J. Palmer - 619-629 Smart Pump–Electronic Health Record (EHR) Interoperability with Auto-Documentation is Associated with Increased Submission of Infusion-Therapy Billing Claims at a Community Hospital
by Tina M. Suess & John W. Beard & Michael Ripchinski & Matthew Eberts & Kevin Patrick & Leo J. P. Tharappel - 631-641 A Cost Analysis of Haemodialysis and Peritoneal Dialysis for the Management of End-Stage Renal Failure At an Academic Hospital in Pretoria, South Africa
by Letlhogonolo Makhele & Moliehi Matlala & Mncengeli Sibanda & Antony P. Martin & Brian Godman - 643-645 Indonesian Social Health Insurance Sample Data are Now Available and Accessible for Research
by Anis Fuad - 647-647 Correction to: A Cost Analysis of Haemodialysis and Peritoneal Dialysis for the Management of End-Stage Renal Failure At an Academic Hospital in Pretoria, South Africa
by Letlhogonolo Makhele & Moliehi Matlala & Mncengeli Sibanda & Antony P. Martin & Brian Godman
September 2019, Volume 3, Issue 3
- 279-280 Extending Life in Duchenne Muscular Dystrophy: Implications for Appraisals of Cost-Effectiveness
by Erik Landfeldt - 281-291 Use of Decision Modelling in Economic Evaluations of Diagnostic Tests: An Appraisal and Review of Health Technology Assessments in the UK
by Yaling Yang & Lucy Abel & James Buchanan & Thomas Fanshawe & Bethany Shinkins - 293-302 Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Nigel Fleeman & Adrian Bagust & Rui Duarte & Marty Richardson & Sarah Nevitt & Angela Boland & Eleanor Kotas & Joanne McEntee & Nicky Thorp - 303-309 Evolution of Average European Medicine Prices: Implications for the Methodology of External Price Referencing
by Sabine Vogler & Peter Schneider & Nina Zimmermann - 311-319 The Worth of a Quality-Adjusted Life-Year in Patients with Diabetes: An Investigation Study using a Willingness-to-Pay Method
by Najme Moradi & Arash Rashidian & Shirin Nosratnejad & Alireza Olyaeemanesh & Marzieh Zanganeh & Leila Zarei - 321-331 Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
by Peter L. Quon & Ying Xiao & Sonja Sorensen & Amir Abbas Tahami Monfared - 333-342 Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study
by Luis Manuel Entrenas Costa & Francisco Casas-Maldonado & José Gregorio Soto Campos & Alicia Padilla-Galo & Alberto Levy & Francisco Javier Álvarez Gutiérrez & Ana P. Gómez-Bastero Fernández & Concepción Morales-García & Rocío Gallego Domínguez & Gustavo Villegas Sánchez & Luis Mateos Caballero & Antonio Pereira-Vega & Cayo García Polo & Gerardo Pérez Chica & Juan José Martín Villasclaras - 343-350 Estimated Versus Observed Expenditure Associated with Medicines Recommended by the All Wales Medicines Strategy Group
by Stuart Keeping & Paul N. Deslandes & Kathryn E. Haines & Philip A. Routledge - 351-358 The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q
by Dawn Lee & Nic Brereton & Sujith Dhanasiri & Austin Kulasekararaj - 359-365 Remote Monitoring of Patient-Reported Outcomes in Ulcerative Colitis: A Prospective Real-World Pilot Study
by Shaji Sebastian & Jenna Roberts & John Waller & Davneet Judge & Chloe Brown & Ruth Davies & Sumesh Kachroo - 367-375 Associations between Health-Related Quality of Life and Self-Reported Emergency Room Department Visits and Inpatient Hospitalizations: Insights from a Secondary Data Analysis of Patients with Light-Chain (AL) Amyloidosis
by Kristen L. McCausland & Avery A. Rizio & Michelle K. White & Martha S. Bayliss & Tiffany P. Quock - 377-390 Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma
by Ash Bullement & Paul Nathan & Anna Willis & Amerah Amin & Cameron Lilley & Ceilidh Stapelkamp & Anthony Hatswell & Chris Pescott & Murtuza Bharmal - 391-402 Cost of Treatment of Valvular Heart Disease at a Tertiary Hospital in North India: Policy Implications
by Shankar Prinja & Yashpaul Sharma & Jyoti Dixit & Shyam Kumar Singh Thingnam & Rajesh Kumar - 403-410 A Review of Issues Affecting the Efficiency of Decision Making in the NICE Single Technology Appraisal Process
by M. J. Walton & J. O’Connor & C. Carroll & L. Claxton & R. Hodgson - 411-417 Costs of Acute Headache Medication Use and Productivity Losses Among Patients with Migraine: Insights from Three Randomized Controlled Trials
by Joshua K. Porter & Gian Luca Di Tanna & Richard B. Lipton & Sandhya Sapra & Guillermo Villa - 419-422 All-Male Panels and Gender Diversity of Issue Panels and Plenary Sessions at ISPOR Europe
by Jacoline C. Bouvy & Michelle Mujoomdar - 423-426 All Male Panels and Other Diversity Considerations for ISPOR
by Nancy J. Devlin - 427-427 Correction to: Conducting a Time Trade-Off Study Alongside a Clinical Trial: A Case Study and Recommendations
by Jing Shen & Sarah Hill & David Mott & Matthew Breckons & Luke Vale & Rob Pickard
June 2019, Volume 3, Issue 2
- 129-132 Evaluating the Outcomes Associated with Genomic Sequencing: A Roadmap for Future Research
by James Buchanan & Sarah Wordsworth - 133-141 Working with Patients and Members of the Public: Informing Health Economics in Child Health Research
by Rebecca Kandiyali & Annie Hawton & Christie Cabral & Julie Mytton & Valerie Shilling & Christopher Morris & Jenny Ingram - 143-150 Measuring the Benefits of Decision Aids for Economic Evaluation
by Thomas Butt - 151-161 Strimvelis® for Treating Severe Combined Immunodeficiency Caused by Adenosine Deaminase Deficiency: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Evaluation
by Emily South & Edward Cox & Nick Meader & Nerys Woolacott & Susan Griffin - 163-176 Uterotonic Drugs for the Prevention of Postpartum Haemorrhage: A Cost-Effectiveness Analysis
by Karen Pickering & Ioannis D. Gallos & Helen Williams & Malcolm J. Price & Abi Merriel & David Lissauer & Aurelio Tobias & G. Justus Hofmeyr & Arri Coomarasamy & Tracy E. Roberts - 177-188 Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate
by Bruno Emond & Kruti Joshi & Antoine C. El Khoury & Marie-Hélène Lafeuille & Dominic Pilon & Neeta Tandon & Hela Romdhani & Patrick Lefebvre - 189-195 Cost Comparison of Single-Use Versus Reusable Bronchoscopes Used for Percutaneous Dilatational Tracheostomy
by Anne Sohrt & Lars Ehlers & Flemming Witt Udsen & Anders Mærkedahl & Brendan A. McGrath - 197-204 The Psychometric Properties of a Self-Administered, Open-Source Module for Valuing Metastatic Epidural Spinal Cord Compression Utilities
by Markian Pahuta & Aaron Frombach & Emile Hashem & Stewart Spence & Christina Sun & Eugene K. Wai & Joel Werier & Carl Walraven & Doug Coyle - 205-213 High Healthcare Resource Use in Hospitalized Patients with a Diagnosis of Spinal Muscular Atrophy Type 1 (SMA1): Retrospective Analysis of the Kids’ Inpatient Database (KID)
by Jessica Cardenas & Melissa Menier & Marjet D. Heitzer & Douglas M. Sproule - 215-227 Does Structured Exercise Improve Cognitive Impairment in People with Mild to Moderate Dementia? A Cost-Effectiveness Analysis from a Confirmatory Randomised Controlled Trial: The Dementia and Physical Activity (DAPA) Trial
by Iftekhar Khan & Stavros Petrou & Kamran Khan & Dipesh Mistry & Ranjit Lall & Bart Sheehan & Sarah Lamb - 229-235 Time and Cost of Hospitalisation for Salvage Therapy in Adults with Philadelphia Chromosome-Negative B Cell Precursor Relapsed or Refractory Acute Lymphoblastic Leukaemia in Spain
by Blanca Boluda & Rebeca Rodríguez-Veiga & David Martínez-Cuadrón & Ignacio Lorenzo & Jaime Sanz & Ana Regadera & Amparo Sempere & Leonor Senent & Jose Vicente Cervera & Pilar Solves & John Reitan & Salvador Gea & Miguel Angel Sanz & Pau Montesinos - 237-245 Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States
by Jill A. Bell & Aaron Galaznik & Marlo Blazer & Huai-Che Shih & Eileen Farrelly & Augustina Ogbonnaya & Michael Eaddy & Robert J. Fram & Douglas V. Faller - 247-254 Economics of Acromegaly Treatment in Brazil: A Budget Impact Analysis of Pituitary Surgery Compared with Long-Term Octreotide LAR
by Lara Benigno Porto & Ivan Ricardo Zimmermann & Luciana Ansaneli Naves - 255-264 Patient and Physician Preferences for Therapy Characteristics for Psoriasis: A Discrete Choice Experiment in Japan
by Timothy Bolt & Hisanori Kobayashi & Jörg Mahlich - 265-272 Cost-Effectiveness Analysis of Single-Use EEG Cup Electrodes Compared with Reusable EEG Cup Electrodes
by Anne Sohrt & Anders Mærkedahl & William V. Padula - 273-273 Correction to: Cost-Effectiveness Analysis of Single-Use EEG Cup Electrodes Compared with Reusable EEG Cup Electrodes
by Anne Sohrt & Anders Mærkedahl & William V. Padula - 275-275 Correction to: Cost-Effectiveness Analysis of Single-Use EEG Cup Electrodes Compared with Reusable EEG Cup Electrodes
by Anne Sohrt & Anders Mærkedahl & William V. Padula - 277-277 Correction to: Which Costs Matter? Costs Included in Economic Evaluation and their Impact on Decision Uncertainty for Stable Coronary Artery Disease
by James Lomas & Miqdad Asaria & Laura Bojke & Chris P. Gale & Gerry Richardson & Simon Walker
March 2019, Volume 3, Issue 1
- 1-3 Value Assessment Frameworks in the United States: A Call for Patient Engagement
by Vakaramoko Diaby & Askal A. Ali & Alberto J. Montero - 5-20 Conducting a Time Trade-Off Study Alongside a Clinical Trial: A Case Study and Recommendations
by Jing Shen & Sarah Hill & David Mott & Matthew Breckons & Luke Vale & Rob Pickard - 21-30 Systematic Review of Economic Models Used to Compare Techniques for Detecting Peripheral Arterial Disease
by Eoin Moloney & Joanne O’Connor & Dawn Craig & Shannon Robalino & Alexandros Chrysos & Mehdi Javanbakht & Andrew Sims & Gerard Stansby & Scott Wilkes & John Allen - 31-42 Accommodation and Health Costs of Deinstitutionalized People with Mental Illness Living in Residential Services in Brazil
by Denise Razzouk - 43-54 Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England
by D. Lee & A. Amadi & J. Sabater & J. Ellis & H. Johnson & S. Kotapati & S. McNamara & A. Walker & M. Cooper & K. Patterson & N. Roskell & Y. Meng - 55-69 Reduction of Direct Health Costs Associated with Pertussis Vaccination with Acellular Vaccines in Children Aged 0–9 Years with Pertussis in Catalonia (Spain)
by Pedro Plans-Rubió & Encarna Navas & Pere Godoy & Gloria Carmona & Angela Domínguez & Mireia Jané & Carmen Muñoz-Almagro & Pedro Brotons - 71-80 Assessing the Impact of Growth Hormone Deficiency (GHD) in Adults: Interpreting Change of the Treatment-Related Impact Measure—Adult Growth Hormone Deficiency (TRIM-AGHD)
by Meryl Brod & Jane F. Beck & Lise Højbjerre & Donald M. Bushnell & Johan Erpur Adalsteinsson & Lars Wilkinson & Michael Højby Rasmussen - 81-91 Influence of Idiopathic Pulmonary Fibrosis Progression on Healthcare Resource Use
by Alex Diamantopoulos & Toby M. Maher & Nils Schoof & Dirk Esser & Corinne LeReun - 93-102 Cost Effectiveness of Long-Term Incobotulinumtoxin-A Treatment in the Management of Post-stroke Spasticity of the Upper Limb from the Australian Payer Perspective
by Koji Makino & Dominic Tilden & Carmel Guarnieri & Mia Mudge & Ian J. Baguley - 103-117 International HTA Experience with Targeted Therapy Approvals for Lung Cancer
by Fatma Maraiki & J. Byrnes & H. Tuffaha & M. Hinder - 119-126 Evaluation of the Impact of an Institution-Specific Dofetilide Initiation Protocol on Mean Hospital Length of Stay and Cost for Dofetilide Initiation
by Steven P. Kennedy & Hanna Iaizzo & Evgueni Fayn & Dalip Singh - 127-127 Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England
by D. Lee & A. Amadi & J. Sabater & J. Ellis & H. Johnson & S. Kotapati & S. McNamara & A. Walker & M. Cooper & K. Patterson & N. Roskell & Y. Meng
December 2018, Volume 2, Issue 4
- 357-358 Including Future Consumption and Production in Economic Evaluation of Interventions that Save Life-Years: Commentary
by Erik Nord & Christoffer Lamøy - 359-369 Longitudinal Effects of Adjuvant Endocrine Therapy on the Quality of Life of Post-menopausal Women with Non-metastatic ER+ Breast Cancer: A Systematic Review
by Hong Xiao & Xinyi Jiang & Cheng Chen & Alberto J. Montero & Vakaramoko Diaby - 371-380 Cost-Effectiveness of Aspirin Adherence for Secondary Prevention of Cardiovascular Events
by Laurence M. Djatche & Stefan Varga & Robert D. Lieberthal - 381-392 Functional Status and Well-Being in People with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Compared with People with Multiple Sclerosis and Healthy Controls
by Caroline C. Kingdon & Erinna W. Bowman & Hayley Curran & Luis Nacul & Eliana M. Lacerda - 393-402 Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006–2014
by David Nathanson & Ugne Sabale & Jan W. Eriksson & Thomas Nyström & Anna Norhammar & Urban Olsson & Johan Bodegård - 403-413 Which Costs Matter? Costs Included in Economic Evaluation and their Impact on Decision Uncertainty for Stable Coronary Artery Disease
by James Lomas & Miqdad Asaria & Laura Bojke & Chris P. Gale & Gerry Richardson & Simon Walker - 415-421 Out-of-Pocket Household Expenditures on Medical Injections in Cambodia
by Sachiko Ozawa & Tatenda T. Yemeke & Alie F. Tawah & Vivek Kulkarni & Manuela Villar Uribe - 423-432 Utilization and Expenditure of Anti-cancer Medicines in Kosovo: Findings and Implications
by Arianit Jakupi & Brian Godman & Antony Martin & Alan Haycox & Indrit Baholli - 433-442 The Healthcare Cost Burden of Acute Myocardial Infarction in Alberta, Canada
by Dat T. Tran & Arto Ohinmaa & Nguyen X. Thanh & Robert C. Welsh & Padma Kaul - 443-458 An Exploratory Study: A Head-to-Head Comparison of the EQ-5D-5L and AQoL-8D for Long-Term Publicly Waitlisted Bariatric Surgery Patients Before and 3 Months After Bariatric Surgery
by Julie A. Campbell & Martin Hensher & Amanda Neil & Alison Venn & Petr Otahal & Stephen Wilkinson & Andrew J. Palmer - 459-467 The Cost of Patients with Chronic Kidney Failure Before Dialysis: Results from the IRIDE Observational Study
by Claudio Jommi & Patrizio Armeni & Margherita Battista & Paolo Procolo & Giuseppe Conte & Claudio Ronco & Mario Cozzolino & Anna Maria Costanzo & Umberto Luzio Paparatti & Gabriella Concas & Giuseppe Remuzzi
September 2018, Volume 2, Issue 3
- 221-224 Hospital Pharmacists in Europe: Between Warehouse and Prescription Pad?
by Livio Garattini & Anna Padula - 225-231 Developing Accessible, Pictorial Versions of Health-Related Quality-of-Life Instruments Suitable for Economic Evaluation: A Report of Preliminary Studies Conducted in Canada and the United Kingdom
by David G. T. Whitehurst & Nicholas R. Latimer & Aura Kagan & Rebecca Palmer & Nina Simmons-Mackie & J. Charles Victor & Jeffrey S. Hoch - 233-239 A Review of Clinical and Economic Evaluations Applied to Psychotropic Therapies Used in the Treatment of Schizophrenia in Argentina
by Gisela Paula González & Nebel Silvana Moscoso & Fernando Pablo Lago - 241-253 The Cost Effectiveness of Lubiprostone in Chronic Idiopathic Constipation
by Becky Pennington & Emily-Ruth Marriott & Peter Lichtlen & Ayesha Akbar & Anthony J. Hatswell - 255-270 The Potential Clinical and Economic Value of Primary Tumour Identification in Metastatic Cancer of Unknown Primary Tumour: A Population-Based Retrospective Matched Cohort Study
by Malek B. Hannouf & Eric Winquist & Salaheddin M. Mahmud & Muriel Brackstone & Sisira Sarma & George Rodrigues & Peter K. Rogan & Jeffrey S. Hoch & Gregory S. Zaric - 271-280 Cost Effectiveness of Stapled Haemorrhoidopexy and Traditional Excisional Surgery for the Treatment of Haemorrhoidal Disease
by Mary M. Kilonzo & Steven R. Brown & Hanne Bruhn & Jonathan A. Cook & Jemma Hudson & John Norrie & Angus J. M. Watson & Jessica Wood - 281-296 Out-of-Pocket Expenditures, Indirect Costs and Health-Related Quality of Life of Patients with Pulmonary Tuberculosis in Thailand
by Pimwara Tanvejsilp & Mark Loeb & Jonathan Dushoff & Feng Xie - 297-308 Healthcare Resource Uses and Out-of-Pocket Expenses Associated with Pulmonary TB Treatment in Thailand
by Pimwara Tanvejsilp & Mark Loeb & Jonathan Dushoff & Feng Xie - 309-323 Using Cerebrospinal Fluid Biomarker Testing to Target Treatment to Patients with Mild Cognitive Impairment: A Cost-Effectiveness Analysis
by Tzeyu L. Michaud & Robert L. Kane & J. Riley McCarten & Joseph E. Gaugler & John A. Nyman & Karen M. Kuntz - 325-335 Impact of Fluid Choice in Systemic Inflammatory Response Syndrome Patients on Hospital Cost Savings
by Suzanne Laplante & Dilip U. Makhija & Sibyl H. Munson & Victor S. Khangulov & Fred W. Peyerl & Scott M. Paluszkiewicz & Aditi J. Ravindranath & Carol R. Schermer - 337-345 Evaluation of Health Status of Type 2 Diabetes Outpatients Receiving Care in a Tertiary Hospital in Nigeria
by Maxwell Ogochukwu Adibe & Chibueze Anosike & Sunday Odunke Nduka & Abdulmuminu Isah - 347-354 Cost Analysis of a Digital Health Care Model in Sweden
by Björn Ekman
June 2018, Volume 2, Issue 2
- 87-91 The Impact of Brexit on Pharmaceuticals and HTA
by Paula K Lorgelly - 93-95 Raise the Bar, Not the Threshold Value: Meeting Patient Preferences for Palliative and End-of-Life Care
by Nikki McCaffrey & Simon Eckermann - 97-107 Does Methodological Guidance Produce Consistency? A Review of Methodological Consistency in Breast Cancer Utility Value Measurement in NICE Single Technology Appraisals
by Micah Rose & Stephen Rice & Dawn Craig - 109-123 Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends
by Trevor Jozef Piatkiewicz & Janine Marie Traulsen & Tove Holm-Larsen - 125-139 The Economic Burden of Small Cell Lung Cancer: A Systematic Review of the Literature
by Ashley Enstone & Maire Greaney & Manca Povsic & Robin Wyn & John R. Penrod & Yong Yuan - 141-151 Economic Evaluation of Midazolam–Droperidol Combination, Versus Droperidol or Olanzapine for the Management of Acute Agitation in the Emergency Department: A Within-Trial Analysis
by Celene Y. L. Yap & Ya-seng (Arthur) Hsueh & Jonathan C. Knott & David McD Taylor & Esther W. Chan & David C. M. Kong - 153-163 Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
by Martina Garau & Grace Hampson & Nancy Devlin & Nicola Amedeo Mazzanti & Antonio Profico - 165-177 Direct Mapping of the QLQ-C30 to EQ-5D Preferences: A Comparison of Regression Methods
by Ralph Crott - 179-190 Cost of Intensive Care Treatment for Liver Disorders at Tertiary Care Level in India
by Shankar Prinja & Pankaj Bahuguna & Ajay Duseja & Manmeet Kaur & Yogesh Kumar Chawla - 191-201 Resources and Costs Associated with the Treatment of Advanced and Metastatic Gastric Cancer in the Mexican Public Sector: A Patient Chart Review
by Miguel Quintana & José A. Toriz & Diego Novick & Kyla Jones & Brenda S. Botello & Juan Alejandro Silva - 203-208 Health-Related Quality of Life in Patients Treated with Continuous Ambulatory Peritoneal Dialysis and Automated Peritoneal Dialysis in Singapore
by F. Yang & N. Luo & T. Lau & Z. L. Yu & M. W. Y. Foo & K. Griva - 209-219 Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis
by Bernard Charbonnel & Dominique Simon & Jean Dallongeville & Isabelle Bureau & Sylvie Dejager & Laurie Levy-Bachelot & Julie Gourmelen & Bruno Detournay
March 2018, Volume 2, Issue 1
- 1-3 Health Technology Assessment for Policy Making in India: Current Scenario and Way Forward
by Shankar Prinja & Laura E. Downey & Vijay K. Gauba & Soumya Swaminathan - 5-17 Application of Discrete-Choice Experiment Methods in Tobacco Control: A Systematic Review
by Kabindra Regmi & Dinesh Kaphle & Sabina Timilsina & Nik Annie Afiqah Tuha - 19-29 Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada
by Graeme Ball & Feng Xie & Jean-Eric Tarride - 31-41 Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims Data
by Jacqueline Nicholas & Aaron Boster & Ning Wu & Wei-Shi Yeh & Monica Fay & Jon Kendter & Ming-Yi Huang & Andrew Lee - 43-51 Weighting Health Outcomes by Socioeconomic Position Using Stated Preferences
by Anita Lal & Mohammad Siahpush & Marjory Moodie & Anna Peeters & Robert Carter - 53-61 Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants
by Ahva Shahabi & Desi Peneva & Devin Incerti & Kimmie McLaurin & Warren Stevens - 63-76 An Exploratory Study of Long-Term Publicly Waitlisted Bariatric Surgery Patients’ Quality of Life Before and 1 Year After Bariatric Surgery, and Considerations for Healthcare Planners
by Julie A. Campbell & Martin Hensher & Amanda Neil & Alison Venn & Stephen Wilkinson & Andrew J. Palmer - 77-85 Reliability and Validity of the Greek Migraine Disability Assessment (MIDAS) Questionnaire
by Theodora Oikonomidi & Michail Vikelis & Artemios Artemiadis & George P. Chrousos & Christina Darviri
December 2017, Volume 1, Issue 4
- 233-239 Statistical Alchemy: Conceptual Validity and Mapping to Generate Health State Utility Values
by Jeff Round & Annie Hawton - 241-253 Choosing Between Unicompartmental and Total Knee Replacement: What Can Economic Evaluations Tell Us? A Systematic Review
by Edward Burn & Alexander D. Liddle & Thomas W. Hamilton & Sunil Pai & Hemant G. Pandit & David W. Murray & Rafael Pinedo-Villanueva - 255-263 Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR)
by Lisa Masucci & Jaclyn Beca & Mona Sabharwal & Jeffrey S. Hoch - 265-278 Utilization of Intergovernmental Funds to Implement Maternal and Child Health Plans of a Multi-Strategy Community Intervention in Haryana, North India: A Retrospective Assessment
by Madhu Gupta & Federica Angeli & Hans Bosma & Shankar Prinja & Manmeet Kaur & Onno C. P. Schayck - 279-290 Economic Evaluation of Fulvestrant 500 mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden
by Ugne Sabale & Mattias Ekman & Daniel Thunström & Claire Telford & Christopher Livings - 291-300 Eliciting the Monetary Value of a Quality-Adjusted Life Year in a Greek Outpatient Department in Times of Economic Austerity
by A. Mavrodi & V. Aletras & A. Spanou & D. Niakas - 301-314 Development of a Procedure for the Government Provision of Bone-Anchored Prosthesis Using Osseointegration in Australia
by Laurent Frossard & Gregory Merlo & Tanya Quincey & Brendan Burkett & Debra Berg
September 2017, Volume 1, Issue 3
- 145-147 Can Price Transparency Contribute to More Affordable Patient Access to Medicines?
by Sabine Vogler & Kenneth R. Paterson - 149-165 Model-Based Economic Evaluation of Treatments for Depression: A Systematic Literature Review
by Spyros Kolovos & Judith E. Bosmans & Heleen Riper & Karine Chevreul & Veerle M. H. Coupé & Maurits W. Tulder - 167-173 Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology
by Kavisha Jayasundara & Murray Krahn & Muhammad Mamdani & Jeffrey S. Hoch & Paul Grootendorst - 175-184 Cost-Effectiveness of Haemorrhoidal Artery Ligation versus Rubber Band Ligation for the Treatment of Grade II–III Haemorrhoids: Analysis Using Evidence from the HubBLe Trial
by Abualbishr Alshreef & Allan J. Wailoo & Steven R. Brown & James P. Tiernan & Angus J. M. Watson & Katie Biggs & Mike Bradburn & Daniel Hind - 185-194 Evaluating the Treatment Costs for Uncomplicated Malaria at a Public Healthcare Facility in Nigeria and the Implications
by Charles C. Ezenduka & Daniel Resende Falleiros & Brian B. Godman - 195-202 Cost of Illness of Japanese Patients with Chronic Lymphocytic Leukemia (CLL), and Budget Impact of the Market Introduction of Ibrutinib
by Jörg Mahlich & Shinichiro Okamoto & Akiko Tsubota - 203-221 Health System Efficiency: A Fragmented Picture Based on OECD Data
by Andreas Behr & Katja Theune - 223-229 Cost-Minimisation Analysis of Erythropoiesis-Stimulating Agents in the Treatment of Anaemia in Dialysed Patients: A Pilot Study
by Astrid Darsonval & Virginie Besson & Claire Cavalin
June 2017, Volume 1, Issue 2
- 73-77 Model Registration: A Call to Action
by Christopher James Sampson & Tim Wrightson - 79-97 Handling Missing Data in Within-Trial Cost-Effectiveness Analysis: A Review with Future Recommendations
by Andrea Gabrio & Alexina J. Mason & Gianluca Baio - 99-108 Issues Related to the Frequency of Exploratory Analyses by Evidence Review Groups in the NICE Single Technology Appraisal Process
by Eva Kaltenthaler & Christopher Carroll & Daniel Hill-McManus & Alison Scope & Michael Holmes & Stephen Rice & Micah Rose & Paul Tappenden & Nerys Woolacott - 109-115 A Comparison of Inpatient Cost Per Day in General Surgery Patients with Type 2 Diabetes Treated with Basal-Bolus versus Sliding Scale Insulin Regimens
by Victoria L. Phillips & Anwar L. Byrd & Saira Adeel & Limin Peng & Dawn D. Smiley & Guillermo E. Umpierrez - 117-121 Cost-Benefit Analysis of Telemedicine Systems/Units in Greek Remote Areas
by Marios-Nikolaos Kouskoukis & Charalambos Botsaris - 123-131 Utilization, Spending, and Price Trends for Quinolones in the US Medicaid Programs: 25 Years’ Experience 1991–2015
by Ziyad S. Almalki & Xiaomeng Yue & Ying Xia & Patricia R. Wigle & Jeff Jianfei Guo - 133-141 Early Assessment of the Likely Cost Effectiveness of Single-Use Flexible Video Bronchoscopes
by Christoffer Lilja Terjesen & Julia Kovaleva & Lars Ehlers - 143-143 Erratum to: Handling Missing Data in Within-Trial Cost-Effectiveness Analysis: A Review with Future Recommendations
by Andrea Gabrio & Alexina J. Mason & Gianluca Baio
March 2017, Volume 1, Issue 1
- 1-12 The Potential Cost-Effectiveness of HIV Vaccines: A Systematic Review
by Blythe Adamson & Dobromir Dimitrov & Beth Devine & Ruanne Barnabas - 13-23 Communal Sharing and the Provision of Low-Volume High-Cost Health Services: Results of a Survey
by Jeff Richardson & Angelo Iezzi & Gang Chen & Aimee Maxwell - 25-36 Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
by Jameel Nazir & Malin Berling & Charles McCrea & Francis Fatoye & Sally Bowditch & Zalmai Hakimi & Adrian Wagg - 37-51 Population Screening for Hereditary Haemochromatosis in Australia: Construction and Validation of a State-Transition Cost-Effectiveness Model
by Barbara Graaff & Lei Si & Amanda L. Neil & Kwang Chien Yee & Kristy Sanderson & Lyle C. Gurrin & Andrew J. Palmer - 53-63 A Single-Center Cost Analysis of Treating Primary and Metastatic Brain Cancers with Either Brain Laser Interstitial Thermal Therapy (LITT) or Craniotomy
by Eric C. Leuthardt & Jeff Voigt & Albert H. Kim & Pete Sylvester - 65-68 Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review
by Ilke Akpinar & Philip Jacobs & Tien Dat Tran - 69-70 Comment on: “Forecasting Pharmaceutical Prices for Economic Evaluations When There is No Market: A Review”
by Przemysław Holko - 71-71 Authors’ Reply to Holko: “Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review”
by Ilke Akpinar & Philip Jacobs & Dat T. Tran